Redx, Jounce announce recommended business combination EP News Bureau Feb 24, 2023 Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective…
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic… EP News Bureau Nov 9, 2020 Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877
